TTK Activators
The chemical class known as TTK Activators encompasses a group of compounds that either directly stimulate the activity of the Dual specificity protein kinase TTK (TTK) or indirectly influence its activation by modulating key signaling pathways interconnected with TTK regulation. TTK, also known as Monopolar spindle 1 (Mps1), is a crucial kinase involved in the control of mitosis and cell cycle progression. Its precise regulation is vital for accurate chromosome segregation during cell division, making it an attractive target for understanding cellular processes and potential research applications.
These TTK activators primarily consist of small molecules that interact with specific cellular pathways. Some chemicals, such as SB-431542 and LY3214996, selectively inhibit TGF-β type I receptor kinase, indirectly leading to TTK activation through the TGF-β signaling pathway. Others, like PD-0325901 and U0126, are MEK inhibitors that indirectly affect TTK by modulating the MAPK pathway, which interfaces with TTK regulation. Similarly, PI3-kinase inhibitors like LY294002 and Wortmannin indirectly activate TTK by suppressing PI3-kinase and affecting the downstream AKT/mTOR pathway, thereby influencing TTK activity. Additionally, JNK, p38 MAPK, GSK-3, and mTOR inhibitors can indirectly activate TTK by impacting signaling pathways intricately associated with TTK regulation.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB-431542 is a selective inhibitor of TGF-β type I receptor kinase, which indirectly influences TTK through the TGF-β signaling pathway. Inhibition of TGF-β receptor can activate TTK. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3-kinase inhibitor. Inhibition of PI3-kinase can lead to the downregulation of AKT, which can activate TTK through the AKT/mTOR pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent PI3-kinase inhibitor, which can indirectly activate TTK by inhibiting PI3-kinase and affecting downstream signaling, such as the AKT/mTOR pathway. | ||||||
LY3214996 | 1951483-29-6 | sc-507299 | 5 mg | $265.00 | ||
LY3214996 is a selective TGF-β receptor kinase inhibitor that influences TTK through the TGF-β signaling pathway. Inhibition of TGF-β receptor can activate TTK. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that indirectly affects TTK activation by inhibiting the mTOR pathway, potentially leading to TTK activation due to pathway inhibition. | ||||||
AZD5363 | 1143532-39-1 | sc-503190 | 5 mg | $309.00 | ||
AZD5363 is an AKT kinase inhibitor. Inhibition of AKT can lead to the activation of TTK through the AKT/mTOR pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor, which indirectly affects TTK activation by inhibiting the JNK pathway, potentially leading to TTK activation due to pathway dampening. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. Inhibition of p38 MAPK can influence TTK activation indirectly by affecting the p38 MAPK pathway, which is interconnected with TTK regulation. | ||||||
LY2090314 | 603288-22-8 | sc-507359 | 5 mg | $175.00 | ||
LY2090314 is a selective GSK-3 inhibitor. Inhibition of GSK-3 can activate TTK indirectly through the regulation of Wnt/β-catenin signaling, which interacts with TTK. | ||||||
TGF-β RI Kinase Inhibitor VIII | 356559-20-1 | sc-203295 | 2 mg | $100.00 | 2 | |
SB-525334 is a selective TGF-β receptor I kinase inhibitor that indirectly influences TTK through the TGF-β signaling pathway. Inhibition of TGF-β receptor can activate TTK. | ||||||